These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 38061684)
21. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555 [TBL] [Abstract][Full Text] [Related]
24. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776 [TBL] [Abstract][Full Text] [Related]
25. Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing. Rowlands CF; Allen S; Balmaña J; Domchek SM; Evans DG; Hanson H; Hoogerbrugge N; James PA; Nathanson KL; Robson M; Tischkowitz M; Foulkes WD; Turnbull C Ann Oncol; 2024 Oct; 35(10):892-901. PubMed ID: 38986768 [TBL] [Abstract][Full Text] [Related]
26. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels. Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J; Int J Cancer; 2019 Nov; 145(10):2682-2691. PubMed ID: 30927264 [TBL] [Abstract][Full Text] [Related]
27. Increased Risk of Hereditary Prostate Cancer in Italian Families with Hereditary Breast and Ovarian Cancer Syndrome Harboring Mutations in D'Elia G; Caliendo G; Tzioni MM; Albanese L; Passariello L; Molinari AM; Vietri MT Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292577 [TBL] [Abstract][Full Text] [Related]
28. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246 [TBL] [Abstract][Full Text] [Related]
29. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727 [TBL] [Abstract][Full Text] [Related]
30. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. LaDuca H; Polley EC; Yussuf A; Hoang L; Gutierrez S; Hart SN; Yadav S; Hu C; Na J; Goldgar DE; Fulk K; Smith LP; Horton C; Profato J; Pesaran T; Gau CL; Pronold M; Davis BT; Chao EC; Couch FJ; Dolinsky JS Genet Med; 2020 Feb; 22(2):407-415. PubMed ID: 31406321 [TBL] [Abstract][Full Text] [Related]
31. PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina. Gonzalez A; Del Greco F; Vargas-Roig L; Brun B; Tabares G; Mampel A; Montes C; Martin C; Lopez M; Rossi N; Bruno L; Ponce C; Quaglio P; Yanzi A; Acevedo S; Lugo L; Lopez Breccia P; Avila S; Sisterna S; Del Castillo MS; Vazquez M; Nuñez LM Breast Cancer Res Treat; 2022 Jul; 194(2):403-412. PubMed ID: 35610400 [TBL] [Abstract][Full Text] [Related]
32. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077 [TBL] [Abstract][Full Text] [Related]
33. Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene. Morgan RD; Burghel GJ; Flaum N; Schlecht H; Clamp AR; Hasan J; Mitchell C; Salih Z; Moon S; Hogg M; Lord R; Forde C; Lalloo F; Woodward ER; Crosbie EJ; Taylor SS; Jayson GC; Evans DGR Genet Med; 2024 Oct; 26(10):101230. PubMed ID: 39096152 [TBL] [Abstract][Full Text] [Related]
34. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition]. Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C; Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633 [TBL] [Abstract][Full Text] [Related]
35. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan. Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218 [TBL] [Abstract][Full Text] [Related]
36. The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024). Kleiblová P; Novotný J; Cibula D; Curtisová V; Dubová O; Foretová L; Germanová A; Janatová M; Havránek O; Hojsáková M; Hudcová M; Koudová M; Krutílková V; Palacova M; Paulich S; Petrakova K; Presl J; Puchmajerová A; Soukupová J; Šenkeříková M; Šimková Z; Štěpánková H; Šubrt I; Tachecí I; Tesner P; Urban O; Veselá K; Vilímová Š; Vlčková Z; Vočka M; Weinberger V; Zikán M; Zimovjanová M; Kleibl Z Klin Onkol; 2024; 38(4):292-299. PubMed ID: 39174333 [TBL] [Abstract][Full Text] [Related]
37. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge. Bono M; Fanale D; Incorvaia L; Cancelliere D; Fiorino A; Calò V; Dimino A; Filorizzo C; Corsini LR; Brando C; Madonia G; Cucinella A; Scalia R; Barraco N; Guadagni F; Pedone E; Badalamenti G; Russo A; Bazan V ESMO Open; 2021 Aug; 6(4):100235. PubMed ID: 34371384 [TBL] [Abstract][Full Text] [Related]
38. Germline mutations in a DNA repair pathway are associated with familial colorectal cancer. Xu P; Sun D; Gao Y; Jiang Y; Zhong M; Zhao G; Chen J; Wang Z; Liu Q; Hong J; Chen H; Chen YX; Fang JY JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549727 [TBL] [Abstract][Full Text] [Related]
39. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628 [TBL] [Abstract][Full Text] [Related]
40. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]